Skip to main
CADL
CADL logo

Candel Therapeutics (CADL) Stock Forecast & Price Target

Candel Therapeutics (CADL) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Candel Therapeutics Inc. has demonstrated a positive trend in median overall survival for its investigational therapy CAN-2409, with notable increases observed in both prostate and pancreatic cancer, leading to higher probabilities of FDA approval of 45% and 40%, respectively. The compelling overall survival results are expected to sustain a strong performance in upcoming pivotal trials, thereby enhancing the company's prospects for clinical success. Additionally, promising outcomes from the Phase 1b trial, which showed significant increases in CD8+ tumor infiltrating lymphocytes following CAN-2409 treatment, further bolster the outlook for its continued development in non-small cell lung cancer (NSCLC).

Bears say

Candel Therapeutics, a clinical-stage biopharmaceutical company, faces a negative outlook primarily due to potential underperformance in the efficacy of its key candidates, CAN-2409 and CAN-3110, in comparison to alternative treatment modalities, which could hinder their market acceptance. The company's financial position is strained, with a reported net loss of $14.1 million in the fourth quarter of 2024, raising concerns about the need for additional capital raises that could lead to significant dilution for existing investors. Furthermore, various risks, including the potential for extended clinical trial requirements, unproven commercialization strategies, and challenges in meeting regulatory expectations, could adversely impact the company's future performance and investor confidence.

Candel Therapeutics (CADL) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Candel Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Candel Therapeutics (CADL) Forecast

Analysts have given Candel Therapeutics (CADL) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Candel Therapeutics (CADL) has a Strong Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Candel Therapeutics (CADL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.